Literature DB >> 2344115

Busulfan and veno-occlusive disease of the liver.

G Vassal, O Hartmann, E Benhamou.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2344115     DOI： 10.7326/0003-4819-112-11-881_1

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  6 in total

1.  Will high dose chemotherapy followed by autologous bone marrow transplantation supplant cranio-spinal irradiation in young children treated for medulloblastoma?

Authors:  S Dupuis-Girod; O Hartmann; E Benhamou; F Doz; F Mechinaud; E Bouffet; C Coze; C Kalifa
Journal:  J Neurooncol       Date:  1996-01       Impact factor: 4.130

Review 2.  The role of busulfan in bone marrow transplantation.

Authors:  M Hassan
Journal:  Med Oncol       Date:  1999-09       Impact factor: 3.064

3.  Gas-chromatographic analysis of busulfan for therapeutic drug monitoring.

Authors:  L Embree; R B Burns; J R Heggie; G L Phillips; D E Reece; J J Spinelli; D O Hartley; N J Hudon; J H Goldie
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

4.  Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation.

Authors:  G Vassal; S Koscielny; D Challine; D Valteau-Couanet; I Boland; A Deroussent; J Lemerle; A Gouyette; O Hartmann
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

5.  Impact of busulfan pharmacokinetics on outcome in adult patients receiving an allogeneic hematopoietic cell transplantation.

Authors:  Claire Seydoux; Raphael Battegay; Joerg Halter; Dominik Heim; Katharina M Rentsch; Jakob R Passweg; Michael Medinger
Journal:  Bone Marrow Transplant       Date:  2022-03-31       Impact factor: 5.174

6.  Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial.

Authors:  Claire Seydoux; Michael Medinger; Sabine Gerull; Joerg Halter; Dominik Heim; Yves Chalandon; Stavroula Masouridi Levrat; Urs Schanz; Gayathri Nair; Marc Ansari; Patrick Simon; Jakob R Passweg; Nathan Cantoni
Journal:  Ann Hematol       Date:  2020-10-23       Impact factor: 3.673
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.